Bioanalytical aspects of clinical mass balance studies in oncology. - Wikidata - wikimedia - TriplyDB

Bioanalytical aspects of clinical mass balance studies in oncology.

Bioanalytical aspects of clinical mass balance studies in oncology.

http://www.wikidata.org/entity/Q37963912

about

Combined quantification of paclitaxel, docetaxel and ritonavir in human feces and urine using LC-MS/MS.Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients.Metabolite profiling of the multiple tyrosine kinase inhibitor lenvatinib: a cross-species comparison.Metabolite profiling of 14C-omacetaxine mepesuccinate in plasma and excreta of cancer patients.

P2860

Q31136016-48834098-10B8-4AC2-8C20-5407AE574B1D Q45383453-EAABAF25-7480-4BBE-BFE2-F2C7D98E9332 Q46573222-EB47C50E-BEE7-4EA9-9FE7-0F97CA0F7244 Q53792398-1E11A40F-A49E-4B71-8845-6BD05F62DE85

P2860

Bioanalytical aspects of clinical mass balance studies in oncology.

http://www.wikidata.org/entity/Q37963912

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Bioanalytical aspects of clinical mass balance studies in oncology.

@en

Bioanalytical aspects of clinical mass balance studies in oncology.

@nl

type

label

Bioanalytical aspects of clinical mass balance studies in oncology.

@en

Bioanalytical aspects of clinical mass balance studies in oncology.

@nl

prefLabel

Bioanalytical aspects of clinical mass balance studies in oncology.

@en

Bioanalytical aspects of clinical mass balance studies in oncology.

@nl

P1433

Q37963912-B9FE4B35-1B73-4C74-8742-4BBBF12E5E48

P1476

Q37963912-8D516C64-CB2F-4F39-A0F4-8543CB64D754

P2093

Q37963912-6775440B-3970-49C8-BD48-94E17A38A7E5

Q37963912-6BEFE1EE-E8B1-4C9F-B9A2-F5F02F077FED

Q37963912-99FA22E5-815F-473E-9FC7-696BA027AE6B

Q37963912-A2E90270-F78C-49DF-8825-C2405AA4208D

P2860

Q37963912-014755A1-BE6F-4BD9-A626-F58DF6C76F58

Q37963912-0E91C538-8B80-44ED-9407-D208C24705A4

Q37963912-1DA012CB-FEBD-445F-A2DC-3DEEE110A879

Q37963912-1E85612C-0CEB-431A-A878-BFA73D9E9F5B

Q37963912-1FD7013A-911D-4906-9AFC-0726246BC6B7

Q37963912-2268952C-70F1-4BF4-9119-63486413541E

Q37963912-2688402E-EFD2-425B-BC7F-D9F0ABF8CFA7

Q37963912-27142578-D706-4936-8C6B-E17DF670006E

Q37963912-29438DC3-CFAE-4A00-A861-98B4E577D80A

Q37963912-2A066462-A5CB-4CBA-9BB8-1E7BE5E7978A

P304

Q37963912-B701A649-4DE9-4B79-881A-A015DA1329A2

P31

Q37963912-DE601315-0938-426D-BF05-D68BF78E9628

P356

Q37963912-96115E52-8354-464B-B77E-88569B8F0EDA

P433

Q37963912-68CEBC7A-0D55-4A6F-9F00-541B26248A52

P478

Q37963912-9BA52D77-7669-4C54-A3F3-A6903C91BF3E

P577

Q37963912-B775D5C7-1281-4384-B253-1587D24C6937

P698

Q37963912-0321756D-E276-4F91-B4AB-74D3F217BFC6

P356

P1433

P1476

Bioanalytical aspects of clinical mass balance studies in oncology.

@en

P2093

Anne-Charlotte Dubbelman

http://www.w3.org/2001/XMLSchema#string

Hilde Rosing

http://www.w3.org/2001/XMLSchema#string

Jan H M Schellens

http://www.w3.org/2001/XMLSchema#string

Jos H Beijnen

http://www.w3.org/2001/XMLSchema#string

P2860

Analytical validation of accelerator mass spectrometry for pharmaceutical development

Applicability of bioanalysis of multiple analytes in drug discovery and development: review of select case studies including assay development considerations.

Fragmentation of N-oxides (deoxygenation) in atmospheric pressure ionization: investigation of the activation process.

High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry.

Potential bias and mitigations when using stable isotope labeled parent drug as internal standard for LC-MS/MS quantitation of metabolites.

An accurate-mass-based spectral-averaging isotope-pattern-filtering algorithm for extraction of drug metabolites possessing a distinct isotope pattern from LC-MS data.

Systematic LC-MS/MS bioanalytical method development that incorporates plasma phospholipids risk avoidance, usage of incurred sample and well thought-out chromatography.

Accelerator mass spectrometry in biomedical dosimetry: relationship between low-level exposure and covalent binding of heterocyclic amine carcinogens to DNA

Stable-isotope dilution LC–MS for quantitative biomarker analysis.

Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK data.

P304

2637-2655

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4155/BIO.11.276

http://www.w3.org/2001/XMLSchema#string

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2011-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22136052

http://www.w3.org/2001/XMLSchema#string